Abingdon Health Plc (ABDXF)
Abingdon Health Plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in York, YK, GB. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $30.1M. On trailing twelve-month figures it carries a trailing P/E of -15.45, a net margin of -19.4%. Its beta of 0.16 implies it has historically moved less than the broad market.
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Abingdon Health Plc is most often compared with the following Healthcare names: